nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—ovarian cancer	0.322	1	CbGaD
Carfilzomib—ABCB1—Topotecan—ovarian cancer	0.0298	0.354	CbGbCtD
Carfilzomib—ABCB1—Vinorelbine—ovarian cancer	0.021	0.249	CbGbCtD
Carfilzomib—ABCB1—Paclitaxel—ovarian cancer	0.0148	0.175	CbGbCtD
Carfilzomib—PSMB1—oviduct—ovarian cancer	0.0115	0.0788	CbGeAlD
Carfilzomib—ABCB1—Docetaxel—ovarian cancer	0.0107	0.127	CbGbCtD
Carfilzomib—ABCB1—Doxorubicin—ovarian cancer	0.00795	0.0945	CbGbCtD
Carfilzomib—PSMB8—myometrium—ovarian cancer	0.00476	0.0327	CbGeAlD
Carfilzomib—PSMB10—female reproductive system—ovarian cancer	0.00431	0.0295	CbGeAlD
Carfilzomib—PSMB5—myometrium—ovarian cancer	0.0042	0.0288	CbGeAlD
Carfilzomib—PSMB10—female gonad—ovarian cancer	0.00392	0.0269	CbGeAlD
Carfilzomib—PSMB10—Vinblastine—Vinorelbine—ovarian cancer	0.00373	0.678	CbGdCrCtD
Carfilzomib—PSMB8—uterine cervix—ovarian cancer	0.0037	0.0254	CbGeAlD
Carfilzomib—PSMB1—myometrium—ovarian cancer	0.00368	0.0252	CbGeAlD
Carfilzomib—PSMB2—myometrium—ovarian cancer	0.00359	0.0246	CbGeAlD
Carfilzomib—PSMB1—embryo—ovarian cancer	0.00353	0.0243	CbGeAlD
Carfilzomib—PSMB8—decidua—ovarian cancer	0.00353	0.0242	CbGeAlD
Carfilzomib—PSMB10—testis—ovarian cancer	0.00348	0.0238	CbGeAlD
Carfilzomib—PSMB2—embryo—ovarian cancer	0.00345	0.0237	CbGeAlD
Carfilzomib—PSMB8—endometrium—ovarian cancer	0.00335	0.023	CbGeAlD
Carfilzomib—PSMB5—uterine cervix—ovarian cancer	0.00327	0.0224	CbGeAlD
Carfilzomib—PSMB5—decidua—ovarian cancer	0.00312	0.0214	CbGeAlD
Carfilzomib—PSMB5—endometrium—ovarian cancer	0.00296	0.0203	CbGeAlD
Carfilzomib—PSMB1—uterine cervix—ovarian cancer	0.00286	0.0196	CbGeAlD
Carfilzomib—PSMB2—uterine cervix—ovarian cancer	0.00279	0.0191	CbGeAlD
Carfilzomib—PSMB5—uterus—ovarian cancer	0.00273	0.0187	CbGeAlD
Carfilzomib—PSMB1—decidua—ovarian cancer	0.00272	0.0187	CbGeAlD
Carfilzomib—PSMB2—decidua—ovarian cancer	0.00266	0.0182	CbGeAlD
Carfilzomib—PSMB8—bone marrow—ovarian cancer	0.00262	0.018	CbGeAlD
Carfilzomib—PSMB1—endometrium—ovarian cancer	0.00259	0.0177	CbGeAlD
Carfilzomib—PSMB8—female gonad—ovarian cancer	0.00253	0.0173	CbGeAlD
Carfilzomib—PSMB2—endometrium—ovarian cancer	0.00252	0.0173	CbGeAlD
Carfilzomib—PSMB10—lymph node—ovarian cancer	0.00252	0.0173	CbGeAlD
Carfilzomib—PSMB8—vagina—ovarian cancer	0.00251	0.0172	CbGeAlD
Carfilzomib—PSMB1—gonad—ovarian cancer	0.0024	0.0165	CbGeAlD
Carfilzomib—PSMB1—uterus—ovarian cancer	0.00238	0.0164	CbGeAlD
Carfilzomib—PSMB2—gonad—ovarian cancer	0.00234	0.0161	CbGeAlD
Carfilzomib—PSMB2—uterus—ovarian cancer	0.00233	0.016	CbGeAlD
Carfilzomib—PSMB5—bone marrow—ovarian cancer	0.00231	0.0159	CbGeAlD
Carfilzomib—PSMB8—testis—ovarian cancer	0.00224	0.0154	CbGeAlD
Carfilzomib—PSMB5—female gonad—ovarian cancer	0.00223	0.0153	CbGeAlD
Carfilzomib—PSMB5—vagina—ovarian cancer	0.00222	0.0152	CbGeAlD
Carfilzomib—PSMB1—female reproductive system—ovarian cancer	0.00214	0.0147	CbGeAlD
Carfilzomib—PSMB2—female reproductive system—ovarian cancer	0.00209	0.0143	CbGeAlD
Carfilzomib—PSMB1—bone marrow—ovarian cancer	0.00202	0.0139	CbGeAlD
Carfilzomib—PSMB5—testis—ovarian cancer	0.00198	0.0136	CbGeAlD
Carfilzomib—PSMB2—bone marrow—ovarian cancer	0.00197	0.0135	CbGeAlD
Carfilzomib—PSMB1—female gonad—ovarian cancer	0.00195	0.0134	CbGeAlD
Carfilzomib—PSMB1—vagina—ovarian cancer	0.00194	0.0133	CbGeAlD
Carfilzomib—PSMB2—female gonad—ovarian cancer	0.0019	0.0131	CbGeAlD
Carfilzomib—PSMB2—vagina—ovarian cancer	0.00189	0.013	CbGeAlD
Carfilzomib—PSMB8—Vincristine—Vinorelbine—ovarian cancer	0.00177	0.322	CbGdCrCtD
Carfilzomib—PSMB1—testis—ovarian cancer	0.00173	0.0119	CbGeAlD
Carfilzomib—PSMB2—testis—ovarian cancer	0.00169	0.0116	CbGeAlD
Carfilzomib—PSMB8—lymph node—ovarian cancer	0.00162	0.0111	CbGeAlD
Carfilzomib—PSMB5—lymph node—ovarian cancer	0.00143	0.00984	CbGeAlD
Carfilzomib—PSMB1—lymph node—ovarian cancer	0.00125	0.0086	CbGeAlD
Carfilzomib—PSMB2—lymph node—ovarian cancer	0.00122	0.00839	CbGeAlD
Carfilzomib—Acute coronary syndrome—Vinorelbine—ovarian cancer	0.000629	0.00306	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Vinorelbine—ovarian cancer	0.000625	0.00304	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Paclitaxel—ovarian cancer	0.000614	0.00299	CcSEcCtD
Carfilzomib—Anaemia—Chlorambucil—ovarian cancer	0.000605	0.00295	CcSEcCtD
Carfilzomib—Renal failure acute—Paclitaxel—ovarian cancer	0.000603	0.00294	CcSEcCtD
Carfilzomib—Chills—Topotecan—ovarian cancer	0.000601	0.00292	CcSEcCtD
Carfilzomib—Lopinavir—ABCB1—ovarian cancer	0.000591	0.543	CrCbGaD
Carfilzomib—Neuritis—Epirubicin—ovarian cancer	0.000587	0.00286	CcSEcCtD
Carfilzomib—Leukopenia—Chlorambucil—ovarian cancer	0.000586	0.00285	CcSEcCtD
Carfilzomib—Hypercalcaemia—Doxorubicin—ovarian cancer	0.000584	0.00284	CcSEcCtD
Carfilzomib—Hypoaesthesia—Vinorelbine—ovarian cancer	0.00057	0.00277	CcSEcCtD
Carfilzomib—Sepsis—Docetaxel—ovarian cancer	0.000564	0.00275	CcSEcCtD
Carfilzomib—Back pain—Topotecan—ovarian cancer	0.000564	0.00274	CcSEcCtD
Carfilzomib—Muscle spasms—Topotecan—ovarian cancer	0.00056	0.00273	CcSEcCtD
Carfilzomib—Hyponatraemia—Paclitaxel—ovarian cancer	0.000559	0.00272	CcSEcCtD
Carfilzomib—Pain in extremity—Paclitaxel—ovarian cancer	0.000557	0.00271	CcSEcCtD
Carfilzomib—ABCB1—myometrium—ovarian cancer	0.000548	0.00376	CbGeAlD
Carfilzomib—Neuritis—Doxorubicin—ovarian cancer	0.000543	0.00265	CcSEcCtD
Carfilzomib—Anaemia—Topotecan—ovarian cancer	0.000538	0.00262	CcSEcCtD
Carfilzomib—Cardiac disorder—Vinorelbine—ovarian cancer	0.000531	0.00259	CcSEcCtD
Carfilzomib—Infection—Chlorambucil—ovarian cancer	0.000531	0.00258	CcSEcCtD
Carfilzomib—Cardiac arrest—Paclitaxel—ovarian cancer	0.000529	0.00258	CcSEcCtD
Carfilzomib—Anaemia—Melphalan—ovarian cancer	0.000527	0.00257	CcSEcCtD
Carfilzomib—ABCB1—embryo—ovarian cancer	0.000527	0.00361	CbGeAlD
Carfilzomib—Hepatic failure—Docetaxel—ovarian cancer	0.000525	0.00256	CcSEcCtD
Carfilzomib—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000523	0.00255	CcSEcCtD
Carfilzomib—Leukopenia—Topotecan—ovarian cancer	0.000522	0.00254	CcSEcCtD
Carfilzomib—Blood creatinine increased—Paclitaxel—ovarian cancer	0.000521	0.00254	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Docetaxel—ovarian cancer	0.00052	0.00253	CcSEcCtD
Carfilzomib—Leukopenia—Melphalan—ovarian cancer	0.000511	0.00249	CcSEcCtD
Carfilzomib—Anorexia—Chlorambucil—ovarian cancer	0.000509	0.00248	CcSEcCtD
Carfilzomib—Cough—Topotecan—ovarian cancer	0.000508	0.00248	CcSEcCtD
Carfilzomib—Hypokalaemia—Paclitaxel—ovarian cancer	0.000507	0.00247	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Paclitaxel—ovarian cancer	0.000501	0.00244	CcSEcCtD
Carfilzomib—Cough—Melphalan—ovarian cancer	0.000498	0.00242	CcSEcCtD
Carfilzomib—Ritonavir—ABCB1—ovarian cancer	0.000497	0.457	CrCbGaD
Carfilzomib—Arthralgia—Topotecan—ovarian cancer	0.000496	0.00242	CcSEcCtD
Carfilzomib—Back pain—Vinorelbine—ovarian cancer	0.000482	0.00235	CcSEcCtD
Carfilzomib—Hyponatraemia—Docetaxel—ovarian cancer	0.000474	0.00231	CcSEcCtD
Carfilzomib—Infection—Topotecan—ovarian cancer	0.000472	0.0023	CcSEcCtD
Carfilzomib—Pain in extremity—Docetaxel—ovarian cancer	0.000472	0.0023	CcSEcCtD
Carfilzomib—Thrombocytopenia—Topotecan—ovarian cancer	0.000466	0.00227	CcSEcCtD
Carfilzomib—Decreased appetite—Chlorambucil—ovarian cancer	0.000464	0.00226	CcSEcCtD
Carfilzomib—Infection—Melphalan—ovarian cancer	0.000463	0.00225	CcSEcCtD
Carfilzomib—Anaemia—Vinorelbine—ovarian cancer	0.000461	0.00224	CcSEcCtD
Carfilzomib—Fatigue—Chlorambucil—ovarian cancer	0.00046	0.00224	CcSEcCtD
Carfilzomib—Pain—Chlorambucil—ovarian cancer	0.000457	0.00222	CcSEcCtD
Carfilzomib—Thrombocytopenia—Melphalan—ovarian cancer	0.000456	0.00222	CcSEcCtD
Carfilzomib—Anorexia—Topotecan—ovarian cancer	0.000453	0.00221	CcSEcCtD
Carfilzomib—Neutropenia—Paclitaxel—ovarian cancer	0.00045	0.00219	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Paclitaxel—ovarian cancer	0.000447	0.00218	CcSEcCtD
Carfilzomib—Leukopenia—Vinorelbine—ovarian cancer	0.000446	0.00217	CcSEcCtD
Carfilzomib—Anorexia—Melphalan—ovarian cancer	0.000444	0.00216	CcSEcCtD
Carfilzomib—Cough—Vinorelbine—ovarian cancer	0.000435	0.00212	CcSEcCtD
Carfilzomib—Hyperglycaemia—Paclitaxel—ovarian cancer	0.000434	0.00211	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000433	0.00211	CcSEcCtD
Carfilzomib—Pneumonia—Paclitaxel—ovarian cancer	0.000431	0.0021	CcSEcCtD
Carfilzomib—Hypertension—Vinorelbine—ovarian cancer	0.00043	0.0021	CcSEcCtD
Carfilzomib—ABCB1—epithelium—ovarian cancer	0.00043	0.00295	CbGeAlD
Carfilzomib—ABCB1—uterine cervix—ovarian cancer	0.000426	0.00292	CbGeAlD
Carfilzomib—Aspartate aminotransferase increased—Docetaxel—ovarian cancer	0.000425	0.00207	CcSEcCtD
Carfilzomib—Arthralgia—Vinorelbine—ovarian cancer	0.000424	0.00207	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000424	0.00207	CcSEcCtD
Carfilzomib—Dyspnoea—Topotecan—ovarian cancer	0.000424	0.00206	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Paclitaxel—ovarian cancer	0.000423	0.00206	CcSEcCtD
Carfilzomib—Body temperature increased—Chlorambucil—ovarian cancer	0.000422	0.00206	CcSEcCtD
Carfilzomib—Renal failure—Paclitaxel—ovarian cancer	0.000422	0.00205	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Paclitaxel—ovarian cancer	0.00042	0.00205	CcSEcCtD
Carfilzomib—Dyspnoea—Melphalan—ovarian cancer	0.000415	0.00202	CcSEcCtD
Carfilzomib—Decreased appetite—Topotecan—ovarian cancer	0.000413	0.00201	CcSEcCtD
Carfilzomib—Fatigue—Topotecan—ovarian cancer	0.00041	0.002	CcSEcCtD
Carfilzomib—Constipation—Topotecan—ovarian cancer	0.000407	0.00198	CcSEcCtD
Carfilzomib—Pain—Topotecan—ovarian cancer	0.000407	0.00198	CcSEcCtD
Carfilzomib—ABCB1—decidua—ovarian cancer	0.000406	0.00279	CbGeAlD
Carfilzomib—Decreased appetite—Melphalan—ovarian cancer	0.000405	0.00197	CcSEcCtD
Carfilzomib—Infection—Vinorelbine—ovarian cancer	0.000404	0.00197	CcSEcCtD
Carfilzomib—Fatigue—Melphalan—ovarian cancer	0.000401	0.00195	CcSEcCtD
Carfilzomib—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000398	0.00194	CcSEcCtD
Carfilzomib—Pain—Melphalan—ovarian cancer	0.000398	0.00194	CcSEcCtD
Carfilzomib—Anorexia—Vinorelbine—ovarian cancer	0.000388	0.00189	CcSEcCtD
Carfilzomib—ABCB1—endometrium—ovarian cancer	0.000386	0.00265	CbGeAlD
Carfilzomib—Asthenia—Chlorambucil—ovarian cancer	0.000383	0.00187	CcSEcCtD
Carfilzomib—Hypoaesthesia—Paclitaxel—ovarian cancer	0.000383	0.00187	CcSEcCtD
Carfilzomib—Neutropenia—Docetaxel—ovarian cancer	0.000381	0.00186	CcSEcCtD
Carfilzomib—Sepsis—Epirubicin—ovarian cancer	0.00038	0.00185	CcSEcCtD
Carfilzomib—Oedema peripheral—Paclitaxel—ovarian cancer	0.000379	0.00185	CcSEcCtD
Carfilzomib—Body temperature increased—Topotecan—ovarian cancer	0.000376	0.00183	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000371	0.0018	CcSEcCtD
Carfilzomib—Pneumonia—Docetaxel—ovarian cancer	0.000366	0.00178	CcSEcCtD
Carfilzomib—Diarrhoea—Chlorambucil—ovarian cancer	0.000365	0.00178	CcSEcCtD
Carfilzomib—Dyspnoea—Vinorelbine—ovarian cancer	0.000363	0.00177	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Docetaxel—ovarian cancer	0.000358	0.00175	CcSEcCtD
Carfilzomib—ABCB1—gonad—ovarian cancer	0.000358	0.00245	CbGeAlD
Carfilzomib—Renal failure—Docetaxel—ovarian cancer	0.000357	0.00174	CcSEcCtD
Carfilzomib—Cardiac disorder—Paclitaxel—ovarian cancer	0.000357	0.00174	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Docetaxel—ovarian cancer	0.000356	0.00174	CcSEcCtD
Carfilzomib—ABCB1—uterus—ovarian cancer	0.000355	0.00244	CbGeAlD
Carfilzomib—Hepatic failure—Epirubicin—ovarian cancer	0.000354	0.00172	CcSEcCtD
Carfilzomib—Decreased appetite—Vinorelbine—ovarian cancer	0.000354	0.00172	CcSEcCtD
Carfilzomib—Sepsis—Doxorubicin—ovarian cancer	0.000352	0.00171	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Epirubicin—ovarian cancer	0.000351	0.00171	CcSEcCtD
Carfilzomib—Fatigue—Vinorelbine—ovarian cancer	0.000351	0.00171	CcSEcCtD
Carfilzomib—Constipation—Vinorelbine—ovarian cancer	0.000348	0.00169	CcSEcCtD
Carfilzomib—Pain—Vinorelbine—ovarian cancer	0.000348	0.00169	CcSEcCtD
Carfilzomib—Chills—Paclitaxel—ovarian cancer	0.000346	0.00168	CcSEcCtD
Carfilzomib—Renal failure acute—Epirubicin—ovarian cancer	0.000345	0.00168	CcSEcCtD
Carfilzomib—Asthenia—Topotecan—ovarian cancer	0.000341	0.00166	CcSEcCtD
Carfilzomib—Vomiting—Chlorambucil—ovarian cancer	0.00034	0.00165	CcSEcCtD
Carfilzomib—Asthenia—Melphalan—ovarian cancer	0.000334	0.00163	CcSEcCtD
Carfilzomib—Hepatic failure—Doxorubicin—ovarian cancer	0.000328	0.0016	CcSEcCtD
Carfilzomib—Diarrhoea—Topotecan—ovarian cancer	0.000325	0.00158	CcSEcCtD
Carfilzomib—Hypoaesthesia—Docetaxel—ovarian cancer	0.000325	0.00158	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Doxorubicin—ovarian cancer	0.000325	0.00158	CcSEcCtD
Carfilzomib—Back pain—Paclitaxel—ovarian cancer	0.000324	0.00158	CcSEcCtD
Carfilzomib—Muscle spasms—Paclitaxel—ovarian cancer	0.000322	0.00157	CcSEcCtD
Carfilzomib—Body temperature increased—Vinorelbine—ovarian cancer	0.000322	0.00157	CcSEcCtD
Carfilzomib—Oedema peripheral—Docetaxel—ovarian cancer	0.000322	0.00157	CcSEcCtD
Carfilzomib—Hyponatraemia—Epirubicin—ovarian cancer	0.00032	0.00156	CcSEcCtD
Carfilzomib—ABCB1—female reproductive system—ovarian cancer	0.000319	0.00219	CbGeAlD
Carfilzomib—Renal failure acute—Doxorubicin—ovarian cancer	0.000319	0.00155	CcSEcCtD
Carfilzomib—Diarrhoea—Melphalan—ovarian cancer	0.000319	0.00155	CcSEcCtD
Carfilzomib—Pain in extremity—Epirubicin—ovarian cancer	0.000318	0.00155	CcSEcCtD
Carfilzomib—Nausea—Chlorambucil—ovarian cancer	0.000317	0.00155	CcSEcCtD
Carfilzomib—Dizziness—Topotecan—ovarian cancer	0.000314	0.00153	CcSEcCtD
Carfilzomib—Anaemia—Paclitaxel—ovarian cancer	0.00031	0.00151	CcSEcCtD
Carfilzomib—Cardiac disorder—Docetaxel—ovarian cancer	0.000303	0.00148	CcSEcCtD
Carfilzomib—Cardiac arrest—Epirubicin—ovarian cancer	0.000303	0.00147	CcSEcCtD
Carfilzomib—Vomiting—Topotecan—ovarian cancer	0.000302	0.00147	CcSEcCtD
Carfilzomib—ABCB1—bone marrow—ovarian cancer	0.000302	0.00207	CbGeAlD
Carfilzomib—Leukopenia—Paclitaxel—ovarian cancer	0.0003	0.00146	CcSEcCtD
Carfilzomib—Blood creatinine increased—Epirubicin—ovarian cancer	0.000298	0.00145	CcSEcCtD
Carfilzomib—Headache—Topotecan—ovarian cancer	0.000298	0.00145	CcSEcCtD
Carfilzomib—Vomiting—Melphalan—ovarian cancer	0.000296	0.00144	CcSEcCtD
Carfilzomib—Hyponatraemia—Doxorubicin—ovarian cancer	0.000296	0.00144	CcSEcCtD
Carfilzomib—Pain in extremity—Doxorubicin—ovarian cancer	0.000294	0.00143	CcSEcCtD
Carfilzomib—Chills—Docetaxel—ovarian cancer	0.000293	0.00143	CcSEcCtD
Carfilzomib—Cough—Paclitaxel—ovarian cancer	0.000293	0.00142	CcSEcCtD
Carfilzomib—Asthenia—Vinorelbine—ovarian cancer	0.000292	0.00142	CcSEcCtD
Carfilzomib—ABCB1—female gonad—ovarian cancer	0.000291	0.00199	CbGeAlD
Carfilzomib—Hypokalaemia—Epirubicin—ovarian cancer	0.00029	0.00141	CcSEcCtD
Carfilzomib—Hypertension—Paclitaxel—ovarian cancer	0.000289	0.00141	CcSEcCtD
Carfilzomib—ABCB1—vagina—ovarian cancer	0.000289	0.00198	CbGeAlD
Carfilzomib—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000287	0.0014	CcSEcCtD
Carfilzomib—Arthralgia—Paclitaxel—ovarian cancer	0.000285	0.00139	CcSEcCtD
Carfilzomib—Nausea—Topotecan—ovarian cancer	0.000282	0.00138	CcSEcCtD
Carfilzomib—Cardiac arrest—Doxorubicin—ovarian cancer	0.00028	0.00136	CcSEcCtD
Carfilzomib—Diarrhoea—Vinorelbine—ovarian cancer	0.000278	0.00136	CcSEcCtD
Carfilzomib—Nausea—Melphalan—ovarian cancer	0.000277	0.00135	CcSEcCtD
Carfilzomib—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000276	0.00134	CcSEcCtD
Carfilzomib—Back pain—Docetaxel—ovarian cancer	0.000275	0.00134	CcSEcCtD
Carfilzomib—Muscle spasms—Docetaxel—ovarian cancer	0.000273	0.00133	CcSEcCtD
Carfilzomib—Infection—Paclitaxel—ovarian cancer	0.000272	0.00132	CcSEcCtD
Carfilzomib—Dizziness—Vinorelbine—ovarian cancer	0.000269	0.00131	CcSEcCtD
Carfilzomib—Hypokalaemia—Doxorubicin—ovarian cancer	0.000268	0.00131	CcSEcCtD
Carfilzomib—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000268	0.0013	CcSEcCtD
Carfilzomib—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000265	0.00129	CcSEcCtD
Carfilzomib—Anaemia—Docetaxel—ovarian cancer	0.000263	0.00128	CcSEcCtD
Carfilzomib—Anorexia—Paclitaxel—ovarian cancer	0.000261	0.00127	CcSEcCtD
Carfilzomib—Vomiting—Vinorelbine—ovarian cancer	0.000259	0.00126	CcSEcCtD
Carfilzomib—ABCB1—testis—ovarian cancer	0.000258	0.00177	CbGeAlD
Carfilzomib—Neutropenia—Epirubicin—ovarian cancer	0.000257	0.00125	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Epirubicin—ovarian cancer	0.000256	0.00124	CcSEcCtD
Carfilzomib—Headache—Vinorelbine—ovarian cancer	0.000255	0.00124	CcSEcCtD
Carfilzomib—Leukopenia—Docetaxel—ovarian cancer	0.000254	0.00124	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000249	0.00121	CcSEcCtD
Carfilzomib—Hyperglycaemia—Epirubicin—ovarian cancer	0.000248	0.00121	CcSEcCtD
Carfilzomib—Cough—Docetaxel—ovarian cancer	0.000248	0.00121	CcSEcCtD
Carfilzomib—Insomnia—Paclitaxel—ovarian cancer	0.000247	0.00121	CcSEcCtD
Carfilzomib—Pneumonia—Epirubicin—ovarian cancer	0.000247	0.0012	CcSEcCtD
Carfilzomib—Hypertension—Docetaxel—ovarian cancer	0.000245	0.00119	CcSEcCtD
Carfilzomib—Dyspnoea—Paclitaxel—ovarian cancer	0.000244	0.00119	CcSEcCtD
Carfilzomib—Arthralgia—Docetaxel—ovarian cancer	0.000242	0.00118	CcSEcCtD
Carfilzomib—Nausea—Vinorelbine—ovarian cancer	0.000242	0.00118	CcSEcCtD
Carfilzomib—Renal failure—Epirubicin—ovarian cancer	0.000241	0.00117	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Epirubicin—ovarian cancer	0.00024	0.00117	CcSEcCtD
Carfilzomib—Neutropenia—Doxorubicin—ovarian cancer	0.000238	0.00116	CcSEcCtD
Carfilzomib—Decreased appetite—Paclitaxel—ovarian cancer	0.000238	0.00116	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000237	0.00115	CcSEcCtD
Carfilzomib—Fatigue—Paclitaxel—ovarian cancer	0.000236	0.00115	CcSEcCtD
Carfilzomib—Constipation—Paclitaxel—ovarian cancer	0.000234	0.00114	CcSEcCtD
Carfilzomib—Pain—Paclitaxel—ovarian cancer	0.000234	0.00114	CcSEcCtD
Carfilzomib—Infection—Docetaxel—ovarian cancer	0.00023	0.00112	CcSEcCtD
Carfilzomib—Hyperglycaemia—Doxorubicin—ovarian cancer	0.00023	0.00112	CcSEcCtD
Carfilzomib—Pneumonia—Doxorubicin—ovarian cancer	0.000228	0.00111	CcSEcCtD
Carfilzomib—Thrombocytopenia—Docetaxel—ovarian cancer	0.000227	0.00111	CcSEcCtD
Carfilzomib—Renal failure—Doxorubicin—ovarian cancer	0.000223	0.00109	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000222	0.00108	CcSEcCtD
Carfilzomib—Anorexia—Docetaxel—ovarian cancer	0.000221	0.00108	CcSEcCtD
Carfilzomib—Hypoaesthesia—Epirubicin—ovarian cancer	0.000219	0.00107	CcSEcCtD
Carfilzomib—Oedema peripheral—Epirubicin—ovarian cancer	0.000217	0.00106	CcSEcCtD
Carfilzomib—Body temperature increased—Paclitaxel—ovarian cancer	0.000216	0.00105	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000211	0.00103	CcSEcCtD
Carfilzomib—Insomnia—Docetaxel—ovarian cancer	0.00021	0.00102	CcSEcCtD
Carfilzomib—Dyspnoea—Docetaxel—ovarian cancer	0.000207	0.00101	CcSEcCtD
Carfilzomib—Cardiac disorder—Epirubicin—ovarian cancer	0.000204	0.000995	CcSEcCtD
Carfilzomib—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000203	0.000987	CcSEcCtD
Carfilzomib—Decreased appetite—Docetaxel—ovarian cancer	0.000202	0.000982	CcSEcCtD
Carfilzomib—Oedema peripheral—Doxorubicin—ovarian cancer	0.000201	0.000977	CcSEcCtD
Carfilzomib—Fatigue—Docetaxel—ovarian cancer	0.0002	0.000974	CcSEcCtD
Carfilzomib—Pain—Docetaxel—ovarian cancer	0.000198	0.000966	CcSEcCtD
Carfilzomib—Constipation—Docetaxel—ovarian cancer	0.000198	0.000966	CcSEcCtD
Carfilzomib—Chills—Epirubicin—ovarian cancer	0.000198	0.000962	CcSEcCtD
Carfilzomib—Asthenia—Paclitaxel—ovarian cancer	0.000196	0.000956	CcSEcCtD
Carfilzomib—Cardiac disorder—Doxorubicin—ovarian cancer	0.000189	0.000921	CcSEcCtD
Carfilzomib—Diarrhoea—Paclitaxel—ovarian cancer	0.000187	0.000912	CcSEcCtD
Carfilzomib—ABCB1—lymph node—ovarian cancer	0.000187	0.00128	CbGeAlD
Carfilzomib—Back pain—Epirubicin—ovarian cancer	0.000185	0.000903	CcSEcCtD
Carfilzomib—Muscle spasms—Epirubicin—ovarian cancer	0.000184	0.000897	CcSEcCtD
Carfilzomib—Body temperature increased—Docetaxel—ovarian cancer	0.000183	0.000893	CcSEcCtD
Carfilzomib—Chills—Doxorubicin—ovarian cancer	0.000183	0.00089	CcSEcCtD
Carfilzomib—Dizziness—Paclitaxel—ovarian cancer	0.000181	0.000881	CcSEcCtD
Carfilzomib—Anaemia—Epirubicin—ovarian cancer	0.000177	0.000863	CcSEcCtD
Carfilzomib—Vomiting—Paclitaxel—ovarian cancer	0.000174	0.000847	CcSEcCtD
Carfilzomib—Leukopenia—Epirubicin—ovarian cancer	0.000172	0.000835	CcSEcCtD
Carfilzomib—Back pain—Doxorubicin—ovarian cancer	0.000172	0.000835	CcSEcCtD
Carfilzomib—Headache—Paclitaxel—ovarian cancer	0.000171	0.000835	CcSEcCtD
Carfilzomib—Muscle spasms—Doxorubicin—ovarian cancer	0.00017	0.00083	CcSEcCtD
Carfilzomib—Cough—Epirubicin—ovarian cancer	0.000167	0.000814	CcSEcCtD
Carfilzomib—Asthenia—Docetaxel—ovarian cancer	0.000166	0.00081	CcSEcCtD
Carfilzomib—Hypertension—Epirubicin—ovarian cancer	0.000165	0.000806	CcSEcCtD
Carfilzomib—Anaemia—Doxorubicin—ovarian cancer	0.000164	0.000798	CcSEcCtD
Carfilzomib—Arthralgia—Epirubicin—ovarian cancer	0.000163	0.000795	CcSEcCtD
Carfilzomib—Nausea—Paclitaxel—ovarian cancer	0.000163	0.000791	CcSEcCtD
Carfilzomib—Leukopenia—Doxorubicin—ovarian cancer	0.000159	0.000773	CcSEcCtD
Carfilzomib—Diarrhoea—Docetaxel—ovarian cancer	0.000159	0.000773	CcSEcCtD
Carfilzomib—Infection—Epirubicin—ovarian cancer	0.000155	0.000757	CcSEcCtD
Carfilzomib—Cough—Doxorubicin—ovarian cancer	0.000155	0.000754	CcSEcCtD
Carfilzomib—Dizziness—Docetaxel—ovarian cancer	0.000153	0.000747	CcSEcCtD
Carfilzomib—Thrombocytopenia—Epirubicin—ovarian cancer	0.000153	0.000746	CcSEcCtD
Carfilzomib—Hypertension—Doxorubicin—ovarian cancer	0.000153	0.000746	CcSEcCtD
Carfilzomib—Arthralgia—Doxorubicin—ovarian cancer	0.000151	0.000735	CcSEcCtD
Carfilzomib—Anorexia—Epirubicin—ovarian cancer	0.000149	0.000726	CcSEcCtD
Carfilzomib—Vomiting—Docetaxel—ovarian cancer	0.000147	0.000718	CcSEcCtD
Carfilzomib—Headache—Docetaxel—ovarian cancer	0.000145	0.000707	CcSEcCtD
Carfilzomib—Infection—Doxorubicin—ovarian cancer	0.000144	0.0007	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000143	0.000694	CcSEcCtD
Carfilzomib—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000142	0.00069	CcSEcCtD
Carfilzomib—Insomnia—Epirubicin—ovarian cancer	0.000141	0.000689	CcSEcCtD
Carfilzomib—Dyspnoea—Epirubicin—ovarian cancer	0.000139	0.000679	CcSEcCtD
Carfilzomib—Anorexia—Doxorubicin—ovarian cancer	0.000138	0.000672	CcSEcCtD
Carfilzomib—Nausea—Docetaxel—ovarian cancer	0.000138	0.000671	CcSEcCtD
Carfilzomib—Decreased appetite—Epirubicin—ovarian cancer	0.000136	0.000662	CcSEcCtD
Carfilzomib—Fatigue—Epirubicin—ovarian cancer	0.000135	0.000657	CcSEcCtD
Carfilzomib—Constipation—Epirubicin—ovarian cancer	0.000134	0.000651	CcSEcCtD
Carfilzomib—Pain—Epirubicin—ovarian cancer	0.000134	0.000651	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000132	0.000642	CcSEcCtD
Carfilzomib—Insomnia—Doxorubicin—ovarian cancer	0.000131	0.000637	CcSEcCtD
Carfilzomib—Dyspnoea—Doxorubicin—ovarian cancer	0.000129	0.000628	CcSEcCtD
Carfilzomib—Decreased appetite—Doxorubicin—ovarian cancer	0.000126	0.000613	CcSEcCtD
Carfilzomib—Fatigue—Doxorubicin—ovarian cancer	0.000125	0.000608	CcSEcCtD
Carfilzomib—Constipation—Doxorubicin—ovarian cancer	0.000124	0.000603	CcSEcCtD
Carfilzomib—Pain—Doxorubicin—ovarian cancer	0.000124	0.000603	CcSEcCtD
Carfilzomib—Body temperature increased—Epirubicin—ovarian cancer	0.000124	0.000602	CcSEcCtD
Carfilzomib—Body temperature increased—Doxorubicin—ovarian cancer	0.000114	0.000557	CcSEcCtD
Carfilzomib—Asthenia—Epirubicin—ovarian cancer	0.000112	0.000547	CcSEcCtD
Carfilzomib—Diarrhoea—Epirubicin—ovarian cancer	0.000107	0.000521	CcSEcCtD
Carfilzomib—Asthenia—Doxorubicin—ovarian cancer	0.000104	0.000506	CcSEcCtD
Carfilzomib—Dizziness—Epirubicin—ovarian cancer	0.000103	0.000504	CcSEcCtD
Carfilzomib—Vomiting—Epirubicin—ovarian cancer	9.95e-05	0.000484	CcSEcCtD
Carfilzomib—Diarrhoea—Doxorubicin—ovarian cancer	9.9e-05	0.000482	CcSEcCtD
Carfilzomib—Headache—Epirubicin—ovarian cancer	9.8e-05	0.000477	CcSEcCtD
Carfilzomib—Dizziness—Doxorubicin—ovarian cancer	9.57e-05	0.000466	CcSEcCtD
Carfilzomib—Nausea—Epirubicin—ovarian cancer	9.29e-05	0.000452	CcSEcCtD
Carfilzomib—Vomiting—Doxorubicin—ovarian cancer	9.2e-05	0.000448	CcSEcCtD
Carfilzomib—Headache—Doxorubicin—ovarian cancer	9.07e-05	0.000442	CcSEcCtD
Carfilzomib—Nausea—Doxorubicin—ovarian cancer	8.6e-05	0.000419	CcSEcCtD
Carfilzomib—PSMB9—Signaling Pathways—PTEN—ovarian cancer	1.38e-05	5.85e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CD—ovarian cancer	1.38e-05	5.83e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK3—ovarian cancer	1.37e-05	5.8e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MAPK3—ovarian cancer	1.36e-05	5.77e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	1.36e-05	5.75e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—MYC—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—MYC—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—MYC—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—ovarian cancer	1.34e-05	5.69e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—ovarian cancer	1.34e-05	5.68e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NRAS—ovarian cancer	1.34e-05	5.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NRAS—ovarian cancer	1.34e-05	5.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NRAS—ovarian cancer	1.34e-05	5.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—ovarian cancer	1.33e-05	5.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—MYC—ovarian cancer	1.33e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—ovarian cancer	1.32e-05	5.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—MAPK1—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—MAPK1—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—MAPK1—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—EGFR—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—EGFR—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—EGFR—ovarian cancer	1.32e-05	5.6e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NRAS—ovarian cancer	1.32e-05	5.59e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—MAPK1—ovarian cancer	1.3e-05	5.52e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—EGFR—ovarian cancer	1.3e-05	5.52e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HRAS—ovarian cancer	1.29e-05	5.48e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HRAS—ovarian cancer	1.29e-05	5.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK3—ovarian cancer	1.28e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK3—ovarian cancer	1.28e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK3—ovarian cancer	1.28e-05	5.43e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—YAP1—ovarian cancer	1.27e-05	5.37e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK3—ovarian cancer	1.27e-05	5.36e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PTEN—ovarian cancer	1.26e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PTEN—ovarian cancer	1.26e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PTEN—ovarian cancer	1.26e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	5.31e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—KRAS—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—KRAS—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—KRAS—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MYC—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MYC—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MYC—ovarian cancer	1.25e-05	5.29e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—ovarian cancer	1.25e-05	5.28e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	5.26e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PTEN—ovarian cancer	1.24e-05	5.25e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NRAS—ovarian cancer	1.24e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—ovarian cancer	1.24e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—AKT1—ovarian cancer	1.24e-05	5.24e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—ovarian cancer	1.24e-05	5.23e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—ERBB2—ovarian cancer	1.23e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—ERBB2—ovarian cancer	1.23e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—ERBB2—ovarian cancer	1.23e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NRAS—ovarian cancer	1.23e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—ovarian cancer	1.23e-05	5.22e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—KRAS—ovarian cancer	1.23e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—AKT1—ovarian cancer	1.23e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MYC—ovarian cancer	1.23e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—AKT1—ovarian cancer	1.23e-05	5.21e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—AKT1—ovarian cancer	1.22e-05	5.18e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—MAPK1—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—MAPK1—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—MAPK1—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—EGFR—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—EGFR—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—EGFR—ovarian cancer	1.22e-05	5.17e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CB—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CB—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MTOR—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MTOR—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MTOR—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CB—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—ERBB2—ovarian cancer	1.22e-05	5.15e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—MAPK1—ovarian cancer	1.2e-05	5.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—EGFR—ovarian cancer	1.2e-05	5.1e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MTOR—ovarian cancer	1.2e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CB—ovarian cancer	1.2e-05	5.08e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK3—ovarian cancer	1.19e-05	5.02e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK3—ovarian cancer	1.18e-05	5e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PIK3CA—ovarian cancer	1.17e-05	4.96e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—ovarian cancer	1.17e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—ovarian cancer	1.17e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—ovarian cancer	1.17e-05	4.95e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PIK3CA—ovarian cancer	1.17e-05	4.93e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MYC—ovarian cancer	1.15e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—KRAS—ovarian cancer	1.15e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—KRAS—ovarian cancer	1.15e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—KRAS—ovarian cancer	1.15e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—ovarian cancer	1.15e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MYC—ovarian cancer	1.15e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—PIK3CA—ovarian cancer	1.15e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—PIK3CA—ovarian cancer	1.15e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—PIK3CA—ovarian cancer	1.15e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	1.15e-05	4.86e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CDKN1B—ovarian cancer	1.14e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CDKN1B—ovarian cancer	1.14e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CDKN1B—ovarian cancer	1.14e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—AKT1—ovarian cancer	1.14e-05	4.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—KRAS—ovarian cancer	1.14e-05	4.81e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—AKT1—ovarian cancer	1.14e-05	4.81e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—PIK3CA—ovarian cancer	1.13e-05	4.79e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—MAPK1—ovarian cancer	1.13e-05	4.78e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—EGFR—ovarian cancer	1.13e-05	4.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CDKN1B—ovarian cancer	1.13e-05	4.77e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—MAPK1—ovarian cancer	1.12e-05	4.75e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—EGFR—ovarian cancer	1.12e-05	4.75e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CASP3—ovarian cancer	1.12e-05	4.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CASP3—ovarian cancer	1.12e-05	4.74e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CASP3—ovarian cancer	1.12e-05	4.74e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL2—ovarian cancer	1.12e-05	4.73e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL2—ovarian cancer	1.12e-05	4.73e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL2—ovarian cancer	1.12e-05	4.73e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CASP3—ovarian cancer	1.1e-05	4.67e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL2—ovarian cancer	1.1e-05	4.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CCND1—ovarian cancer	1.09e-05	4.61e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CCND1—ovarian cancer	1.09e-05	4.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CCND1—ovarian cancer	1.09e-05	4.61e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CTNNB1—ovarian cancer	1.08e-05	4.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CTNNB1—ovarian cancer	1.08e-05	4.57e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CTNNB1—ovarian cancer	1.08e-05	4.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CCND1—ovarian cancer	1.07e-05	4.55e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—KRAS—ovarian cancer	1.07e-05	4.51e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CTNNB1—ovarian cancer	1.06e-05	4.5e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HRAS—ovarian cancer	1.06e-05	4.5e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HRAS—ovarian cancer	1.06e-05	4.5e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HRAS—ovarian cancer	1.06e-05	4.5e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—KRAS—ovarian cancer	1.06e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—PIK3CA—ovarian cancer	1.06e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—PIK3CA—ovarian cancer	1.06e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—PIK3CA—ovarian cancer	1.06e-05	4.49e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MMP9—ovarian cancer	1.06e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MMP9—ovarian cancer	1.06e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MMP9—ovarian cancer	1.06e-05	4.48e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PTEN—ovarian cancer	1.05e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PTEN—ovarian cancer	1.05e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PTEN—ovarian cancer	1.05e-05	4.45e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HRAS—ovarian cancer	1.05e-05	4.43e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—PIK3CA—ovarian cancer	1.04e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MMP9—ovarian cancer	1.04e-05	4.42e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PTEN—ovarian cancer	1.04e-05	4.39e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—FASN—ovarian cancer	1.03e-05	4.38e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC5A5—ovarian cancer	1.02e-05	4.31e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—ovarian cancer	1.02e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—ovarian cancer	1.02e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—ovarian cancer	1.02e-05	4.3e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—ovarian cancer	1e-05	4.24e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—SLC2A1—ovarian cancer	9.82e-06	4.16e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HRAS—ovarian cancer	9.8e-06	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HRAS—ovarian cancer	9.8e-06	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HRAS—ovarian cancer	9.8e-06	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—PIK3CA—ovarian cancer	9.79e-06	4.15e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—PIK3CA—ovarian cancer	9.74e-06	4.13e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HRAS—ovarian cancer	9.66e-06	4.09e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—AKT1—ovarian cancer	9.56e-06	4.05e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—AKT1—ovarian cancer	9.52e-06	4.03e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—ovarian cancer	9.5e-06	4.02e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—ovarian cancer	9.5e-06	4.02e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—ovarian cancer	9.5e-06	4.02e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—ovarian cancer	9.47e-06	4.01e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—ovarian cancer	9.43e-06	3.99e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP1B1—ovarian cancer	9.41e-06	3.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—ovarian cancer	9.41e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—ovarian cancer	9.41e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—ovarian cancer	9.41e-06	3.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NRAS—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NRAS—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NRAS—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—ovarian cancer	9.38e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—AKT1—ovarian cancer	9.37e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—AKT1—ovarian cancer	9.37e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—AKT1—ovarian cancer	9.37e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—ovarian cancer	9.36e-06	3.97e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—AKT1—ovarian cancer	9.32e-06	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—AKT1—ovarian cancer	9.32e-06	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—AKT1—ovarian cancer	9.32e-06	3.95e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—ovarian cancer	9.27e-06	3.93e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NRAS—ovarian cancer	9.25e-06	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—ovarian cancer	9.25e-06	3.92e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—AKT1—ovarian cancer	9.24e-06	3.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—AKT1—ovarian cancer	9.19e-06	3.89e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—HRAS—ovarian cancer	9.06e-06	3.84e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—HRAS—ovarian cancer	9.01e-06	3.82e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK3—ovarian cancer	8.99e-06	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK3—ovarian cancer	8.99e-06	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK3—ovarian cancer	8.99e-06	3.81e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PIK3CA—ovarian cancer	8.87e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PIK3CA—ovarian cancer	8.87e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PIK3CA—ovarian cancer	8.87e-06	3.76e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK3—ovarian cancer	8.86e-06	3.75e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PIK3CA—ovarian cancer	8.75e-06	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MYC—ovarian cancer	8.74e-06	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MYC—ovarian cancer	8.74e-06	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MYC—ovarian cancer	8.74e-06	3.7e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—ovarian cancer	8.67e-06	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—AKT1—ovarian cancer	8.65e-06	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—AKT1—ovarian cancer	8.65e-06	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—AKT1—ovarian cancer	8.65e-06	3.67e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—ovarian cancer	8.63e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MYC—ovarian cancer	8.62e-06	3.65e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—MAPK1—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—MAPK1—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—MAPK1—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—EGFR—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—EGFR—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—EGFR—ovarian cancer	8.55e-06	3.62e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—AKT1—ovarian cancer	8.53e-06	3.61e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—MAPK1—ovarian cancer	8.43e-06	3.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—EGFR—ovarian cancer	8.43e-06	3.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPP2R1A—ovarian cancer	8.35e-06	3.54e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—KRAS—ovarian cancer	8.08e-06	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—KRAS—ovarian cancer	8.08e-06	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—KRAS—ovarian cancer	8.08e-06	3.42e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—AKT1—ovarian cancer	8e-06	3.39e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—KRAS—ovarian cancer	7.96e-06	3.37e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—AKT1—ovarian cancer	7.96e-06	3.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—TYMS—ovarian cancer	7.61e-06	3.22e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—PIK3CA—ovarian cancer	7.42e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—PIK3CA—ovarian cancer	7.42e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—PIK3CA—ovarian cancer	7.42e-06	3.14e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—PIK3CA—ovarian cancer	7.31e-06	3.1e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—AKT1—ovarian cancer	7.25e-06	3.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—AKT1—ovarian cancer	7.25e-06	3.07e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—AKT1—ovarian cancer	7.25e-06	3.07e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—ovarian cancer	7.18e-06	3.04e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—ovarian cancer	7.18e-06	3.04e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—ovarian cancer	7.18e-06	3.04e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—AKT1—ovarian cancer	7.15e-06	3.03e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—ovarian cancer	7.08e-06	3e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—HRAS—ovarian cancer	6.86e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—HRAS—ovarian cancer	6.86e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—HRAS—ovarian cancer	6.86e-06	2.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—HRAS—ovarian cancer	6.77e-06	2.87e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—ovarian cancer	6.57e-06	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—ovarian cancer	6.57e-06	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—ovarian cancer	6.57e-06	2.78e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—ovarian cancer	6.48e-06	2.74e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAV1—ovarian cancer	6.13e-06	2.6e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—AKT1—ovarian cancer	6.06e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—AKT1—ovarian cancer	6.06e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—AKT1—ovarian cancer	6.06e-06	2.57e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—AKT1—ovarian cancer	5.98e-06	2.53e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CG—ovarian cancer	5.59e-06	2.37e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CD—ovarian cancer	4.91e-06	2.08e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CB—ovarian cancer	4.28e-06	1.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PTEN—ovarian cancer	3.7e-06	1.57e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PIK3CA—ovarian cancer	2.61e-06	1.11e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—AKT1—ovarian cancer	2.13e-06	9.03e-06	CbGpPWpGaD
